BTTX Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 51.40%

Insider Buying (Last 12 Months): $0.00

Insider Selling (Last 12 Months): $0.00

Better Therapeutics Insider Trading History Chart

Better Therapeutics Share Price & Price History

^$0.00

+0.30 (1.20%)

As of 04/4/2025 11:34 AM ET

Days: 30 | 90 | 365

Better Therapeutics Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
7/27/2023	Andrew J. Armanino	Director	Buy	274,010	$0.73	$200,027.30	728,368
7/27/2023	David P Perry	Chairman	Buy	1,233,045	$0.73	$900,122.85	13,030,393
7/27/2023	Frank Karbe	CEO	Buy	137,005	$0.73	$100,013.65	429,429
7/27/2023	Mark A Berman	Insider	Buy	54,802	$0.73	$40,005.46	388,191
5/16/2023	Elder Granger	Director	Buy	600	$0.87	$522.00	1,600
4/10/2023	Frank Karbe	Insider	Buy	242,424	$0.82	$198,787.68	292,424
4/10/2023	Geoffrey M Parker	Director	Buy	303,030	$0.82	$248,484.60	343,030
9/15/2022	Frank Karbe	Insider	Buy	50,000	$2.09	$104,500.00	50,000
9/12/2022	Mark Heinen	Insider	Buy	23,868	$1.94	$46,303.92	43,868
6/24/2022	Mark Heinen	Insider	Buy	2,281	$1.75	$3,991.75	2,281
6/13/2022	Geoffrey M Parker	Director	Buy	25,000	$1.45	$36,250.00	40,000
6/10/2022	Mark Heinen	Insider	Buy	5,000	$1.56	$7,800.00	20,000

See Full Table

SEC Filings (Institutional Ownership Changes) for Better Therapeutics (NASDAQ:BTTX)

34.00% of Better Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Better Therapeutics Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
2/12/2024	MMCAP International Inc. SPC	356,270	$65K	0.0%	-77.5%	0.715%
11/14/2023	MMCAP International Inc. SPC	1,583,079	$0.58M	0.2%	N/A	3.340%
5/15/2023	Farallon Capital Management LLC	699,042	$0.51M	0.0%	-14.1%	2.931%
5/10/2022	Sectoral Asset Management Inc.	878,531	$1.74M	0.3%	-9.8%	3.721%
5/4/2022	Victory Capital Management Inc.	272,720	$0.54M	0.0%	N/A	1.155%

Data available starting January 2016

Better Therapeutics, Inc., a prescription digital therapeutics company, develops a form of cognitive behavioral therapy to address the causes of cardiometabolic diseases. The company's lead product candidate is BT-001, an investigational PDT platform to treat type 2 diabetes. It also develops software-based prescription digital therapeutics platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions. In addition, the company's clinical development candidates are intended to treat cardiometabolic diseases, including type 2 diabetes, hypertension, hyperlipidemia, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and chronic kidney disease. Its product pipeline also includes BT-002, which intends glycemic control for hypertension; BT-003 to reduce LDL cholesterol in patients with hyperlipidemia; and BT-004, which intends to explore the impact of treatment on liver health in patients with non-alcoholic steatohepatitis/non-alcoholic fatty liver disease. The company was founded in 2015 and is headquartered in San Francisco, California.

Today's Range

Now: $0.00

$0.00

50 Day Range

MA: N/A

52 Week Range

Now: $0.00

$0.00

$0.03

Volume

1,183 shs

Average Volume

20,688 shs

Market Capitalization

$19,944.80

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.14

Who are the company insiders with the largest holdings of Better Therapeutics?: Better Therapeutics' top insider shareholders include:
David P Perry (Chairman)
Andrew J Armanino (Director)
Frank Karbe (CEO)
Mark A Berman (Insider)
Geoffrey M Parker (Director)
Frank Karbe (Insider)
Elder Granger (Director)
Learn More about top insider investors at Better Therapeutics.